通过使用手性Ru(II)催化剂和HCO 2 H / Et 3 N的共沸溶液作为氢供体,通过动态动力学拆分,开发了β-酮磺酰胺的高度对映选择性转移加氢反应,可提供良好的α-取代的β-羟基磺酰胺产生具有优异的非对映选择性和对映选择性的产物。该方法具有条件温和,操作简便,底物范围广的特点,可以在合成天然产物和含有α-取代的β-羟基磺酰胺核心的生物活性化合物中找到广泛的应用。
通过使用手性Ru(II)催化剂和HCO 2 H / Et 3 N的共沸溶液作为氢供体,通过动态动力学拆分,开发了β-酮磺酰胺的高度对映选择性转移加氢反应,可提供良好的α-取代的β-羟基磺酰胺产生具有优异的非对映选择性和对映选择性的产物。该方法具有条件温和,操作简便,底物范围广的特点,可以在合成天然产物和含有α-取代的β-羟基磺酰胺核心的生物活性化合物中找到广泛的应用。
[EN] LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS<br/>[FR] DIAMINES CYCLIQUES CONTENANT DU LACTAME ET LEURS DERIVES UTILISES EN TANT QU'INHIBITEURS DU FACTEUR XA
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2004082687A1
公开(公告)日:2004-09-30
The present application describes lactam-containing cyclic diamines and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein M is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trysin-like serine proteases, specifically factor Xa.
[EN] AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON<br/>[FR] COMPOSÉS D'AMINO-PYRIMIDINE EN TANT QU'INHIBITEURS DE TBKL ET OU D'IKK EPSILON
申请人:MYREXIS INC
公开号:WO2011046970A1
公开(公告)日:2011-04-21
The invention relates to certain amino-pyrimidine compounds which inhibit TBK1 and/or IKK epsilon and which may therefore find application in treating inflammation, cancer, septic shock and/or Primary open Angle Glaucoma (POAG).
Catalytic alkylation reactions of weakly acidic carbonyl and related pronucleophiles such as amides, esters, and sulfonamides with substituted alkenes have been reported. In the presence of a strong Brønsted base catalyst system, potassium hexamethyldisilazide and 18-crown-6 ether, the desired reactions proceeded in high yields at ambient temperature with a wide substrate scope. These are atom-economical
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
申请人:Rodgers D. James
公开号:US20070135461A1
公开(公告)日:2007-06-14
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
[EN] PYRIDONE-SULFONE MORPHINAN ANALOGS AS OPIOID RECEPTOR LIGANDS<br/>[FR] ANALOGUES DE MORPHINANE PYRIDONE-SULFONES UTILISÉS COMME LIGANDS DE RÉCEPTEURS OPIOÏDES
申请人:PURDUE PHARMA LP
公开号:WO2015102682A1
公开(公告)日:2015-07-09
The application is directed to Pyridone-sulfone morphinan analogs compounds of Formula I: or pharmaceutically acceptable salts and solvates thereof, wherein ==, R1, R2, R3, R4 and Z are as defined as set forth in the specification. The invention is also directed to use of the compounds of Formula I or the pharmaceutically acceptable salts and solvates thereof to treat disorders responsive to the odulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.